|Articles|June 12, 2021

COVID-19 Linked With Alzheimer's Disease-Like Dementia

Author(s)Killian Meara

Individuals with the allele APOE E4/E4 were found to be more susceptible.

A recent study conducted by investigators from the Cleveland Clinic has discovered an overlap between an infection with COVID-19 and brain changes that are commonly seen in individuals with Alzheimer’s disease.

Results from the study were published in the journal Alzheimer's Research & Therapy.

"We discovered that SARS-CoV-2 infection significantly altered Alzheimer's markers implicated in brain inflammation and that certain viral entry factors are highly expressed in cells in the blood-brain barrier," Feixiong Cheng, lead author on the study said. "These findings indicate that the virus may impact several genes or pathways involved in neuroinflammation and brain microvascular injury, which could lead to Alzheimer’s disease-like cognitive impairment."

For the study, the team of investigators analyzed datasets of patients with both COVID-19 and Alzheimer’s disease. Using artificial intelligence, they measured the distance between SARS-CoV-2 host genes and those associated with different neurological diseases where closer proximity suggests related or shared disease pathways.

The team also looked at genetic factors which allow the SARS-CoV-2 virus to infect brain cells and tissue.

Findings from the study showed that there was a close network relationship between SARS-CoV-2 and genes/proteins that are associated with some neurological disease such as Alzheimer’s. This could lead to COVID-19 causing Alzheimer's-like dementia.

Additional findings showed that those with the allele APOE E4/E4, had a decreased expression of antiviral defense genes, which could explain why some people are more susceptible.

"While some studies suggest that SARS-CoV-2 infects brain cells directly, others found no evidence of the virus in the brain," Cheng said. "Identifying how COVID-19 and neurological problems are linked will be critical for developing effective preventive and therapeutic strategies to address the surge in neurocognitive impairments that we expect to see in the near future."


Related to this article

Ebola Outbreak Tops 10,000 Cases as CDC Cites Spread to Kenya, Nigeria
The CDC reports the Bundibugyo virus outbreak in the Democratic Republic of the Congo (DRC) is now the second-largest Ebola outbreak on record. As of October 28, the agency counted 10,305 total confirmed cases and 4,996 total confirmed deaths. The overall risk to the American public and travelers remains low, and no cases tied to this outbreak have been confirmed in the US.
Measles Update: October 30, 2026
The latest CDC numbers show a 5.8% increase in measles cases from week-to-week, bringing the 2026 US total to more than double the amount seen in all of 2025 with 2 months left in the year.
Cefiderocol Continues to Show Activity Against Resistant Gram-Negative Infections
Shionogi data presented at IDWeek 2026 demonstrated a 76.7% clinical response with cefiderocol in carbapenem-resistant respiratory infections and high in vitro activity against resistant P aeruginosa VAP isolates. Christine Slover, PharmD, vice president, Infectious Diseases US Medical Affairs, Shionogi, offers insights on the data as well as clinical considerations for providers when weighing the antibiotic for patients.